Pfizer Cash Flow from Investing Activities 2010-2024 | PFE
Pfizer annual/quarterly cash flow from investing activities history and growth rate from 2010 to 2024. Cash flow from investing activities can be defined as the total change in cash resulting from a companies investments
- Pfizer cash flow from investing activities for the quarter ending March 31, 2024 was $1.732B, a 47.75% decline year-over-year.
- Pfizer cash flow from investing activities for the twelve months ending March 31, 2024 was $-73.998B, a 113.95% increase year-over-year.
- Pfizer annual cash flow from investing activities for 2023 was $-32.278B, a 104.51% increase from 2022.
- Pfizer annual cash flow from investing activities for 2022 was $-15.783B, a 30% decline from 2021.
- Pfizer annual cash flow from investing activities for 2021 was $-22.546B, a 427.89% increase from 2020.
Pfizer Annual Cash Flow Investing
(Millions of US $) |
| 2023 |
$-32,278 |
| 2022 |
$-15,783 |
| 2021 |
$-22,546 |
| 2020 |
$-4,271 |
| 2019 |
$-3,945 |
| 2018 |
$4,525 |
| 2017 |
$-4,740 |
| 2016 |
$-7,791 |
| 2015 |
$-2,980 |
| 2014 |
$-5,654 |
| 2013 |
$-10,544 |
| 2012 |
$6,154 |
| 2011 |
$1,843 |
| 2010 |
$-492 |
| 2009 |
$-31,272 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$158.721B |
$58.496B |
|
Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.
|
